Elena Nikulina

Allogene Therapeutics advances ALPHA3 trial data to expand off the shelf CAR T access

Allogene Therapeutics advances ALPHA3 trial data to expand off the shelf CAR T access
Allogene advances ALPHA3 CAR T data

Allogene Therapeutics has released early results from its ALPHA3 trial, highlighting progress in developing investigational off the shelf CAR T therapy for patients with large B cell lymphoma (LBCL).

The company aims to improve access to novel cell therapies, particularly for patients in community healthcare settings. The ALPHA3 program features an allogeneic, or donor-derived, cell therapy product designed to be readily available and patient centered. The move is part of a broader trend among biotech firms to pursue scalable and more accessible cell therapies that could transform cancer care.

Allogene Therapeutics previously outlined its strategy to address the restrictions of autologous CAR T therapies with its AlloCAR T platform. Earlier this year, the company reviewed initial ALPHA3 safety results and discussed the potential role of cema-cel for minimal residual disease-positive LBCL outpatients in community settings. These efforts reflect the firm’s ongoing focus on investigational cell therapies for broader patient access.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.